Business Context and Reporting Period
Company: Psyence Biomedical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: June 2026 (Filed June 5, 2026)
Context: This filing reports a corporate governance action regarding the amendment of the company's equity incentive plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is non-financial in nature and focuses solely on a plan amendment.
Material Changes
On May 4, 2026, the Board of Directors approved a resolution to amend and restate the Psyence Biomedical Ltd. 2023 Equity Incentive Plan. The amendment corrects a typographical error in Section 4(b) of the original plan.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the description of the amended plan is not complete and is qualified by reference to the full text of the First Amended and Restated Plan, which is included as Exhibit 10.1.
Risks and Contingencies: No specific risks, contingencies, or unusual items are disclosed in this filing.
Guidance: No financial guidance or outlook is provided.
Investor Verification Checklist
- Review Exhibit 10.1 to confirm the specific text of the typographical correction in Section 4(b) of the 2023 Equity Incentive Plan.
- Verify that the amendment does not alter the substantive terms or dilution potential of the plan beyond the stated correction.
- Confirm the effective date of the First Amended and Restated Plan as detailed in the full exhibit.